Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2012.0237


Vemurafenib plus cetuximab or gefitinib for BRAF(V600E) mutant colorectal cancer.

Ernst Hanisch, MD.

Affiliation: Prof. Ernst Hanisch, Chefarzt und Ärztlicher Direktor, Klinik für Allgemein- Viszeral- und Endokrine Chirurgie, Asklepios Klinik Langen, Akademisches Lehrkrankenhaus der JWG-Universität Frankfurt, Röntgenstr 20, 63225 Langen.

Tel: 06103/912 61200; FAX: 06103/9121814,


Since there is no abstract available we provide the first paragraph.
The small-molecule drug PLX4032 (vemurafenib) has demonstrated clinical success, approved by the FDA and is currently the standard treatment of BRAF V600E mutant metastatic melanoma. However, response rate of vemurafenib for in roughly 10% of colorectal cancer with BRAF V600E mutation is low (<5%). Could a combination of targeted drugs including EGFR inhibitors and mutant BRAF inhibitors, in addition to standard chemotherapy, improve response and survival rates? These questions and resistance mechanisms to BRAF (V600) oncoprotein inhibition are discussed based on the results of a recent report in Nature [ 1] .

(Citation: Gastric & Breast Cancer 2012; 11(3): 151-153)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 10 July 2012